Returning to Campus

The following approach to help students and faculty understand their risk of COVID-19 exposure was built using guidance from the Centers for Disease Control and Prevention (CDC), and should be adjusted as appropriate to reflect university policy and civic, regional, state, and federal guidance.

The value of antibody testing according to current FDA recommendations

An April 17, 2020 letter from the FDA outlines information and guidance for HCPs regarding the use of antibody testing for COVID-19:

- The FDA recommends that healthcare providers continue to use serological tests intended to detect antibodies to SARS-CoV-2 to help identify people who may have been exposed to the SARS-CoV-2 virus or have recovered from the COVID-19 infection.
- Serological tests can play a critical role in the fight against COVID-19 by helping healthcare professionals identify individuals who may have been exposed to SARS-CoV-2 virus and may have developed an immune response.
- Experience with other viruses suggests that individuals whose blood contains antibodies associated with SARS-CoV-2 infection—provided they are recovered and not currently infected with the virus—may be able to resume work and other daily activities in society.
- Individuals whose blood contains antibodies may also be eligible to serve as potential donors of convalescent plasma.
- The FDA is not aware of an antibody test that has been validated for diagnosis of SARS-CoV-2 infection. Based on the underlying scientific principles of antibody tests, the FDA does not expect that an antibody test can be shown to definitively diagnose or exclude SARS-CoV-2 infection.

For more information on COVID-19, please visit QuestDiagnostics.com/COVID19
The antibody tests (sometimes known as the serology tests or IgG tests) are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS-CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, molecular testing for SARS-CoV-2 is necessary. The antibody test should not be used to diagnose acute SARS-CoV-2 infection. False positive results for the antibody test may occur due to cross-reactivity from pre-existing antibodies or other possible causes.

1. The antibody tests and the molecular tests (together “All tests”) have not been FDA cleared or approved;
2. All tests have been authorized by FDA under EUAs for use by authorized laboratories;
3. The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
4. The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and, 
5. All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Our Back to School solution can help you:

- Help your faculty, staff, students, and their parents understand their risk of exposure
- Make informed decisions about the risk to your faculty and staff
- Develop and implement return-to-campus scenarios
- Lessen the risk of exposure in your classrooms
- Help your students get the education and support they need to excel

To learn more about our Back to School program, contact your Quest Diagnostics sales representative or visit health.questdiagnostics.com/backtoschool

The antibody tests (sometimes known as the serology tests or IgG tests) are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS-CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, molecular testing for SARS-CoV-2 is necessary. The antibody test should not be used to diagnose acute SARS-CoV-2 infection. False positive results for the antibody test may occur due to cross-reactivity from pre-existing antibodies or other possible causes.

1. The antibody tests and the molecular tests (together “All tests”) have not been FDA cleared or approved;
2. All tests have been authorized by FDA under EUAs for use by authorized laboratories;
3. The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
4. The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and, 
5. All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Reference

QuestDiagnostics.com
Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2020 Quest Diagnostics Incorporated. All rights reserved. SB9990 5/2020